Formatech, Inc. Donates Manufacturing Services to RegeneRx Biopharmaceuticals, Inc. to Produce Experimental Drug for the Treatment of Multiple Sclerosis

ANDOVER, Mass.--(BUSINESS WIRE)--Today, Formatech, Inc. announces the selection of RegeneRx Biopharmaceuticals, Inc.’s therapeutic product candidate RGN-352 as the next Fillanthropy™ Program candidate. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in clinical trials.
MORE ON THIS TOPIC